← Back to list
MA08.167, Pozelimab-bbfg (Veopoz®)
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
Independence Blue Cross reissued MA08.167 on 05/27/2026 with no substantive changes to coverage criteria for pozelimab-bbfg (Veopoz®), a complement inhibitor for CD55-deficient protein-losing enteropathy (CHAPLE disease) in patients age 1+. The policy remains unchanged from its original 04/01/2024 effective date; this is a routine reissue to communicate the plan's continuing position on coverage.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 5 steps
01No immediate action required.
02This is a reissue with no changes to coverage criteria, billing codes, or documentation requirements.
03Billing teams should file this reissue in policy records for reference.
04Continue applying the original MA08.167 coverage criteria (effective 04/01/2024) without modification.
05Monitor for future updates if substantive changes are announced.
Codes mentioned
J9376D84.1K90.49
Original notice
MA08.167, Pozelimab-bbfg (Veopoz®)
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.167, Pozelimab-bbfg (Veopoz®)LowNo effective date · Pharmacy08.02.17, Pozelimab-bbfg (Veopoz®)LowEffective Apr 1, 2024 · Pharmacy08.02.17, Pozelimab-bbfg (Veopoz®)LowEffective Apr 1, 2024 · Pharmacy05.00.14s, High-Frequency Chest Wall Oscillation DevicesLowEffective Nov 17, 2025 · Medical PolicyBrowse every Independence Blue Cross change in the policy list